Cancer Theranostics - 1st Edition - ISBN: 9780124077225, 9780124078840

Cancer Theranostics

1st Edition

Editors: Xiaoyuan Chen Stephen Wong
eBook ISBN: 9780124078840
Hardcover ISBN: 9780124077225
Imprint: Academic Press
Published Date: 20th March 2014
Page Count: 544
Tax/VAT will be calculated at check-out
File Compatibility per Device

PDF, EPUB, VSB (Vital Source):
PC, Apple Mac, iPhone, iPad, Android mobile devices.

Amazon Kindle eReader.

Institutional Access


Aiding researchers seeking to eliminate multi-step procedures, reduce delays in treatment and ease patient care, Cancer Theranostics reviews, assesses, and makes pertinent clinical recommendations on the integration of comprehensive in vitro diagnostics, in vivo molecular imaging, and individualized treatments towards the personalization of cancer treatment.

Cancer Theranostics describes the identification of novel biomarkers to advance molecular diagnostics of cancer. The book encompasses new molecular imaging probes and techniques for early detection of cancer, and describes molecular imaging-guided cancer therapy. Discussion also includes nanoplatforms incorporating both cancer imaging and therapeutic components, as well as clinical translation and future perspectives.

Key Features

  • Supports elimination of multi-step approaches and reduces delays in treatments through combinatorial diagnosis and therapy
  • Fully assesses cancer theranostics across the emergent field, with discussion of biomarkers, molecular imaging, imaging guided therapy, nanotechnology, and personalized medicine
  • Content bridges laboratory, clinic, and biotechnology industries to advance biomedical science and improve patient management


Industry and academia working on drug discovery/development, pharmacology, personalized medicine, nanomedicine, medical imaging, imaging guided therapy, biomarkers, molecular pathology, proteomics, genomics, microarray chips, molecular biology.

Table of Contents

  • Preface
  • Acknowledgments
  • About the Editors
  • List of Contributors
  • Part I: In Vitro Diagnostics
    • Chapter 1. Cancer Theranostics: An Introduction
      • Cancer Theranostics: A Definition
      • Theranostic Cancer Biomarkers
      • Molecular Imaging in Cancer Theranostics
      • Imaging-Guided Cancer Therapy
      • Theranostic Platforms
      • Challenges and Future Perspectives
      • References
    • Chapter 2. Genomics-Based Cancer Theranostics
      • Introduction
      • Next Generation Sequencing Technology for Genomics-Based Cancer Theranostics
      • Genomics Landscapes in Common Forms of Human Cancers
      • Functions of Key Signaling Pathways in Cancer
      • Integration of Genomic Screening for Cancer Theranostics
      • Acknowledgments
      • Glossary
      • Abbreviations
      • References
    • Chapter 3. Proteomics-Based Theranostics
      • Introduction
      • Mass Spectrometry Techniques Used for Proteomics Biomarker Discovery
      • Bioinformatics Analysis Pipeline for Proteomics Biomarker Discovery
      • Challenges in Proteomics Biomarker Discovery
      • Existing Single Biomarkers
      • Knowledge-Integrated Network Biomarker Discovery
      • Clinical Validation of Proteomics Biomarkers
      • Glossary
      • Abbreviations
      • References
  • Part II: Molecular Imaging
    • Chapter 4. Radionuclide Imaging of Cancer Therapy
      • Bone Scintigraphy
      • Thyroid Radioiodine Scintigraphy
      • Nonspecific Single-Photon Radiotracers
      • Positron Emission Tomography
      • Conclusion
      • References
    • Chapter 5. Near-Infrared Fluorescence Imaging Probes for Cancer Diagnosis and Treatment
      • Introduction
      • Antibody-Based NIR Probes
      • Peptide-Based NIR Probes
      • Aptamer-Based NIR Probes
      • Polymer-Based NIR Probes
      • Lipid-Based NIR Probes
      • Functional Quantum Dots
      • Functional Upconversion Nanoparticles
      • Clinical Applications and Perspectives
      • Conclusions
      • Acknowledgments
      • References
    • Chapter 6. Bioluminescence Imaging of Cancer Therapy
      • Introduction
      • Preclinical Bioluminescence Imaging for Monitoring Cancer Therapy
      • Therapeutic Evaluation in Rat
      • Conclusion
      • References
    • Chapter 7. Magnetic Resonance Imaging of Cancer Therapy
      • New Trends of Cancer Therapies
      • MR Imaging in Translational Cancer Therapy
      • Necrosis MR Imaging: A Potential Platform for Developing Cancer Theranostics
      • Acknowledgments
      • Abbreviations
      • References
    • Chapter 8. Ultrasound Imaging of Cancer Therapy
      • Introduction
      • Ultrasound Imaging Concepts
      • Assessment of Cancer Therapy
      • Conclusion
      • Acknowledgments
      • Abbreviations
      • Glossary
      • References
    • Chapter 9. Photoacoustic Imaging for Cancer Diagnosis and Therapy Guidance
      • Introduction
      • Operation Principle (Theory)
      • Photoacoustic Anatomical and Functional Imaging: Imaging Cancer with Endogenous Contrast
      • Photoacoustic Molecular Imaging: Imaging Cancer with Exogenous Contrast
      • Photoacoustic Image-Guided Cancer Therapies
      • Outlook
      • References
  • Part III: Imaging-Guided Therapy
    • Chapter 10. Multimodality Image-Guided Lung Intervention Systems
      • Introduction
      • Medical Imaging for Minimally Invasive Intervention
      • Interventional Device Tracking
      • Image-Guided Lung Intervention
      • Conclusion
      • Acronyms and Abbreviations
      • References
    • Chapter 11. Label-Free Molecular Vibrational Imaging for Cancer Diagnosis
      • Introduction
      • Diagnostic Imaging of Prostate Gland and Cavernous Nerves Using CARS
      • CARS for Differential Diagnosis of Human Lung Cancer
      • Suppression of Four-Wave Mixing in Multimode Fibers for Fiber-Delivered CARS Imaging
      • Conclusions and Future Directions
      • Acknowledgments
      • Acronyms and Abbreviations
      • References
    • Chapter 12. Multimodality Image-Guided Treatment
      • Introduction
      • Imaging Modalities in Clinical Cancer Practice
      • Locoregional Cancer Therapy in Clinical Practice
      • Image-Guided Therapy and Multimodality Image-Guided Treatment
      • Possibilities of Multimodality Image-Guided Treatment
      • Limitations of and Requirements for Successful Deployment of Multimodality Image-Guided Treatment
      • Conclusion
      • Acronyms and Abbreviations
      • References
    • Chapter 13. Medical Robotics for Cellular and Molecular Imaging
      • Overview
      • Confocal Endomicroscopy for Detection of Neoplasia
      • Challenges Faced by Confocal Endomicroscopy
      • Robotic Assistance and Computer-Aided Diagnosis
      • Future Work
      • References
  • Part IV: Theranostic Platforms
    • Chapter 14. Porphyrins for Imaging, Photodynamic Therapy, and Photothermal Therapy
      • Optical Imaging, Photodynamic Therapy, and Photothermal Therapy
      • Porphyrins
      • List of Acronyms and Abbreviations
      • References
    • Chapter 15. Magnetic Resonance Imaging and Alternating Magnetic Fields
      • Introduction
      • Key Concepts
      • Magnetic Nanoparticles as Contrast Agents for MRI Application
      • Magnetic Nanoparticles for Therapeutic Applications
      • Prospects and Conclusion
      • References
    • Chapter 16. Ultrasound for Drug/Gene Delivery
      • Barriers to Drug and Gene Delivery to Tumors
      • Biophysics of Therapeutic Ultrasound
      • Ultrasound-Facilitated Drug and Gene Delivery
      • Ultrasound-Responsive Nanoparticles as Drug and Gene Delivery Carriers
      • Therapeutic Applications of Drug and Gene Delivery
      • Potential Pitfalls in Ultrasound-Mediated Delivery into Tumor Tissue
      • Conclusions
      • Acknowledgments
      • References
    • Chapter 17. Radionuclides for Imaging and Therapy in Oncology
      • Introduction
      • Imaging Techniques and Radionuclides
      • Radiotherapy
      • Selection of Radionuclides
      • Theranostics: Dual/Pair Radionuclides
      • Biomarkers and Radiopharmaceutical Development
      • Radiopharmaceuticals in Oncology
      • Conclusion
      • References
    • Chapter 18. Noble Metal Nanoparticle Platform
      • Introduction
      • Physical, Chemical, and Biological Properties
      • Case Studies
      • Opportunities and Challenges
      • Acknowledgments
      • References
    • Chapter 19. Cancer Theranostics with Carbon-Based Nanoplatforms
      • Introduction
      • Fullerenes
      • Carbon Nanotubes
      • Graphene
      • C-Dots
      • Toxicity of Carbon Nanomaterials
      • Conclusion
      • Abbreviations
      • References
    • Chapter 20. Silica Nanoparticle Platform
      • Introduction
      • Biocompatibility
      • Nanoplatform Properties and their Role in Biocompatibility
      • Silica Toxicity
      • Synthesis and Surface Modification of Silica Nanoparticles
      • Silica Nanoparticle Nanotheranostics
      • Conclusions
      • References
    • Chapter 21. Quantum Dots for Traceable Therapeutic Delivery
      • Introduction
      • Design and Synthesis of Theranostic Quantum Dots
      • Applications of Theranostic Quantum Dots
      • Barriers to the Clinical Translation of Theranostic Quantum Dots
      • Perspectives and Conclusions
      • References
    • Chapter 22. Polymer- and Protein-Based Nanotechnologies for Cancer Theranostics
      • Introduction
      • Polymer-Based Theranostic Platform
      • Protein-Based Theranostic Platforms
      • Opportunities and Challenges
      • Acknowledgments
      • References
  • Part V: Other
    • Chapter 23. Clinical Translation and Regulations of Theranostics
      • Introduction
      • Nanomedicine: The Vehicle
      • Molecular Imaging Probes: Linkage and Diagnostic
      • Biomarkers: The Target
      • Anticancer: Therapy
      • Determining Regulatory Requirements
      • Early Phase Trials
      • Investigational Drug Application
      • Combination Products
      • Companion Products
      • Alternate Paths to Regulatory Approval
      • Institutional Review Board
      • Reducing Bias
      • Conclusion
      • Glossary
      • Clinical Trial Phases Devices
      • Clinical Trial Phases (Drugs)
      • References
    • Chapter 24. Scale-Up Production of Theranostic Nanoparticles
      • Introduction
      • Current Preparation Methods of Theranostic Nanoparticles
      • Current Scale-Up Processes
      • Pilot Plant Design for Theranostic Nanoparticles
      • Sterilization
      • Summary and Future Perspectives
      • Acknowledgment
      • References
    • Chapter 25. Market Considerations for Nanomedicines and Theranostic Nanomedicines
      • Key Concepts
      • Introduction
      • Nanotechnologies Enabling Technologies
      • Nanotechnology Applications in Medicine and Business Model Selection
      • Nanotechnology and Nanomedicine Patenting Systems
      • Nanotechnology and Nanomedicine Regulatory, Legal, Ethical, and Policy Issues
      • Conclusion
      • References
    • Chapter 26. Application of Theranostics to Measure and Treat Cell Heterogeneity in Cancer
      • Key Concepts
      • Introduction
      • Different Facets of Cellular Heterogeneity in Cancer
      • Tools to Detect and Measure Cell Heterogeneity
      • New Directions for the Management of Cell Heterogeneity in Cancer Via the Development of Theranostics
      • Conclusion
      • Acknowledgments
      • Glossary
      • Acronyms and Abbreviations
      • References
  • Index


No. of pages:
© Academic Press 2014
Academic Press
eBook ISBN:
Hardcover ISBN:

About the Editor

Xiaoyuan Chen

Xiaoyuan (Shawn) Chen, PhD, is a Senior Investigator and Chief of the Laboratory of Molecular Imaging and Nanomedicine (LOMIN) at the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH). He is also founding editor of journal Theranostics. He holds a PhD in Chemistry from the University of Idaho.

Affiliations and Expertise

Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health

Stephen Wong

Stephen T.C. Wong, PhD (Computer Science), PE (Electrical Engineering), is John S. Dunn Distinguished Endowed Chair of Biomedical Engineering at Houston Methodist Hospital, the Founding Chair of Department of Systems Medicine and Bioengineering at Houston Methodist Research Institute, and a Professor of Radiology, Neurosciences, Pathology, and Laboratory Medicine at Weill Cornell Medical College.

Affiliations and Expertise

Methodist Hospital Research Institute


BMA Medical Book Awards 2015: Highly Commended, Oncology, British Medical Association


", assesses, and makes pertinent clinical recommendations on the integration of comprehensive in vitro diagnostics, in vivo molecular imaging, and individualized treatments…"--Anticancer Research, January 2015